Radiopharmaceutical
-
Radionetics Oncology Enters Into Strategic Agreement With Lilly on its proprietary GPCR targeting small molecule radiopharmaceuticals
Warmest congratulations to Eli Lilly and Radionetics Oncology!
-
This Radiopharma biotech called off the IPO at the last moment before the bell-ringing
DrugTimes will follow up to report further
